Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2.
Barreiro A, Prenafeta A, Bech-Sabat G, Roca M, Perozo Mur E, March R, González-González L, Madrenas L, Corominas J, Fernández A, Moros A, Cañete M, Molas M, Pentinat-Pelegrin T, Panosa C, Moreno A, Puigvert Molas E, Pol Vilarrassa E, Palmada J, Garriga C, Prat Cabañas T, Iglesias-Fernández J, Vergara-Alert J, Lorca-Oró C, Roca N, Fernández-Bastit L, Rodon J, Pérez M, Segalés J, Pradenas E, Marfil S, Trinité B, Ortiz R, Clotet B, Blanco J, Díaz Pedroza J, Ampudia Carrasco R, Rosales Salgado Y, Loubat-Casanovas J, Capdevila Larripa S, Prado JG, Barretina J, Sisteré-Oró M, Cebollada Rica P, Meyerhans A, Ferrer L. Barreiro A, et al. Among authors: ortiz r. iScience. 2023 Mar 17;26(3):106126. doi: 10.1016/j.isci.2023.106126. Epub 2023 Feb 2. iScience. 2023. PMID: 36748086 Free PMC article.
SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity.
Trinité B, Tarrés-Freixas F, Rodon J, Pradenas E, Urrea V, Marfil S, Rodríguez de la Concepción ML, Ávila-Nieto C, Aguilar-Gurrieri C, Barajas A, Ortiz R, Paredes R, Mateu L, Valencia A, Guallar V, Ruiz L, Grau E, Massanella M, Puig J, Chamorro A, Izquierdo-Useros N, Segalés J, Clotet B, Carrillo J, Vergara-Alert J, Blanco J. Trinité B, et al. Among authors: ortiz r. Sci Rep. 2021 Jan 28;11(1):2608. doi: 10.1038/s41598-021-81862-9. Sci Rep. 2021. PMID: 33510275 Free PMC article.
Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals.
Trinité B, Pradenas E, Marfil S, Rovirosa C, Urrea V, Tarrés-Freixas F, Ortiz R, Rodon J, Vergara-Alert J, Segalés J, Guallar V, Lepore R, Izquierdo-Useros N, Trujillo G, Trapé J, González-Fernández C, Flor A, Pérez-Vidal R, Toledo R, Chamorro A, Paredes R, Blanco I, Grau E, Massanella M, Carrillo J, Clotet B, Blanco J. Trinité B, et al. Among authors: ortiz r. Viruses. 2021 Jun 12;13(6):1135. doi: 10.3390/v13061135. Viruses. 2021. PMID: 34204754 Free PMC article.
Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection.
Pradenas E, Trinité B, Urrea V, Marfil S, Tarrés-Freixas F, Ortiz R, Rovirosa C, Rodon J, Vergara-Alert J, Segalés J, Guallar V, Valencia A, Izquierdo-Useros N, Noguera-Julian M, Carrillo J, Paredes R, Mateu L, Chamorro A, Toledo R, Massanella M, Clotet B, Blanco J. Pradenas E, et al. Among authors: ortiz r. Cell Rep Med. 2022 Jan 24;3(2):100523. doi: 10.1016/j.xcrm.2022.100523. eCollection 2022 Feb 15. Cell Rep Med. 2022. PMID: 35233547 Free PMC article.
The Characteristics of the HIV-1 Env Glycoprotein Are Linked With Viral Pathogenesis.
Pérez-Yanes S, Pernas M, Marfil S, Cabrera-Rodríguez R, Ortiz R, Urrea V, Rovirosa C, Estévez-Herrera J, Olivares I, Casado C, Lopez-Galindez C, Blanco J, Valenzuela-Fernández A. Pérez-Yanes S, et al. Among authors: ortiz r. Front Microbiol. 2022 Mar 24;13:763039. doi: 10.3389/fmicb.2022.763039. eCollection 2022. Front Microbiol. 2022. PMID: 35401460 Free PMC article.
Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization.
Pradenas E, Marfil S, Urrea V, Trigueros M, Pidkova T, Pons-Grífols A, Ortiz R, Rovirosa C, Tarrés-Freixas F, Aguilar-Gurrieri C, Toledo R, Chamorro A, Noguera-Julian M, Mateu L, Blanco I, Grau E, Massanella M, Carrillo J, Clotet B, Trinité B, Blanco J. Pradenas E, et al. Among authors: ortiz r. iScience. 2023 Apr 21;26(4):106457. doi: 10.1016/j.isci.2023.106457. Epub 2023 Mar 20. iScience. 2023. PMID: 36999095 Free PMC article.
An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses.
Tarrés-Freixas F, Aguilar-Gurrieri C, Rodríguez de la Concepción ML, Urrea V, Trinité B, Ortiz R, Pradenas E, Blanco P, Marfil S, Molinos-Albert LM, Barajas A, Pons-Grífols A, Ávila-Nieto C, Varela I, Cervera L, Gutiérrez-Granados S, Segura MM, Gòdia F, Clotet B, Carrillo J, Blanco J. Tarrés-Freixas F, et al. Among authors: ortiz r. NPJ Vaccines. 2023 Apr 6;8(1):51. doi: 10.1038/s41541-023-00648-4. NPJ Vaccines. 2023. PMID: 37024469 Free PMC article.
Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2.
Leal L, Pich J, Ferrer L, Nava J, Martí-Lluch R, Esteban I, Pradenas E, Raïch-Regué D, Prenafeta A, Escobar K, Pastor C, Ribas-Aulinas M, Trinitè B, Muñoz-Basagoiti J, Domenech G, Clotet B, Corominas J, Corpes-Comes A, Garriga C, Barreiro A, Izquierdo-Useros N, Arnaiz JA, Soriano A, Ríos J, Nadal M, Plana M, Blanco J, Prat T, Torroella E, Ramos R; HIPRA-HH-1 study group. Leal L, et al. NPJ Vaccines. 2023 Sep 29;8(1):147. doi: 10.1038/s41541-023-00736-5. NPJ Vaccines. 2023. PMID: 37775521 Free PMC article.
1,117 results